Biogen said on Monday it will cut the price of a newish drug for Alzheimer's from Jan. 1. Wall Street had already mostly given up on the therapy, amid questions over whether it even works and glacial uptake – sales were well below $1 million last quarter. Biogen’s market value, at $35 billion, is below where it was prior to U.S. approval of the therapy in June.
A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021.said on Monday it will cut the price of a newish drug for Alzheimer's from Jan. 1. Wall Street had already mostly given up on the therapy, amid questions over whether it even works and glacial uptake – sales were well below $1 million last quarter. Biogen’s market value, at $35 billion, is below where it was prior to U.S. approval of the therapy in June.of drugs every January.
That said, the initial price of $56,000 per year for Biogen's drug was too high. The Institute for Clinical and Economic Review, whose estimates are followed closely by insurers, said it was cost effective at no more thanA lower price might persuade some insurers and government programs like Medicare to cover the cost of the drug based on the hopeit does something.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Biogen cuts the price tag on its Alzheimer's drug in halfBiogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50% next month. Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to “financial considerations,” and their disease had progressed beyond the point where Aduhelm could help.
Weiterlesen »
Biogen Cuts Price for Alzheimer’s Drug Aduhelm by HalfBiogen is slashing the price of its controversial new Alzheimer’s disease treatment Aduhelm in half in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.
Weiterlesen »
Biogen Cuts Price for Alzheimer’s Drug Aduhelm by HalfBiogen is slashing the price of its controversial new Alzheimer’s disease treatment Aduhelm in half in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.
Weiterlesen »
Biogen cuts the price tag on its Alzheimer's drug in halfBiogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50% next month. Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to “financial considerations,” and their disease had progressed beyond the point where Aduhelm could help.
Weiterlesen »
EU set to back Novavax Covid vaccineThe EU's drug regulator will decide Monday whether to approve a Covid jab by Novavax, which uses a more conventional technology that the US biotech firm hopes will reduce vaccine hesitancy.
Weiterlesen »